文献速递白血病

评估伊马替尼作为慢性髓性白血病一线治疗:随机CML研究IV的10年生存结果及非CML决定因素的影响

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
PubMed 文献 · Leukemia · 2017-08-14

CML研究IV将1551例新诊断慢性期患者随机分入5组,比较伊马替尼400 mg/日与双倍剂量、加干扰素、加阿糖胞苷或干扰素失败后使用伊马替尼。中位观察9.5年,10年总生存82%、无进展生存80%、相对生存92%;伊马替尼400 mg与各实验组生存无差异,生存更多由患者和疾病因素决定。

要点

  • 伊马替尼400 mg/日与各实验优化方案组间生存无差异。
  • 10年总生存82%、无进展生存80%、相对生存92%。
  • 3、6、12个月达到分子学缓解里程碑者生存显著更优。

核心结论

  • 对于应答者,伊马替尼400 mg单药治疗可提供接近正常的预期寿命,且与应答时间无关。
  • 生存更多由患者和疾病因素而非初始治疗选择决定。
  • 尽管难治性疾病仍需改善,目前通过仔细处理非CML生存决定因素可赢得更多生存时间。

研究设计与样本

  • CML研究IV为5臂随机研究,2002年7月至2012年3月纳入1551例新诊断慢性期患者。
  • 分组为伊马替尼400 mg/日(n=400)、双倍剂量(n=420)、加干扰素(n=430)、加阿糖胞苷(n=158)或干扰素失败后使用伊马替尼(n=128)。
  • 研究把握度设定为检测5年时5%的生存差异。

主要发现

  • 中位观察9.5年,10年总生存82%、10年无进展生存80%、10年相对生存92%。
  • 伊马替尼400 mg与任何实验组之间生存无差异。
  • 多因素分析中,风险组、主要途径染色体异常、合并症、吸烟和治疗中心(学术与其他)显著影响生存,而任何形式的治疗优化均未显著影响生存。
  • 3、6和12个月达到分子学缓解里程碑的患者具有显著生存优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017. PMID: 28804124. doi:10.1038/leu.2017.253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。